PCI Biotech Announces Upcoming H1 2025 Results Presentation
In an eagerly anticipated event, PCI Biotech (OSE: PCIB) is inviting stakeholders to join a live webcast presentation of its interim report for the first half of 2025. This insightful event is scheduled for a Friday morning slot, allowing participants to engage with the company’s findings and strategic initiatives.
Details of the Presentation
The presentation will take place on a Friday, from 08:30 AM to 09:00 AM CET. Conducted in Norwegian, participants will be able to access the session through the company’s official website, providing an excellent opportunity for those who follow the company closely.
Interactive Q&A Session
At the conclusion of the presentation, there will be a Q&A segment that encourages participant interaction. Attendees are invited to submit their questions in advance to the company’s designated email. Additionally, there will be an option to pose questions live during the session, fostering an engaging atmosphere for all attendees.
Accessing the Interim Report
Participants looking for in-depth insights can find the interim report and presentation materials on the company’s information portal and news web interface at 07:00 AM CET on the same day. This early access allows investors and analysts to review the materials prior to the live discussion.
Contacting the Company
For further queries or information, PCI Biotech encourages direct communication, highlighting the availability of the CEO and CFO, Ronny Skuggedal. Contact can be made through email or mobile, ensuring that stakeholders have access to any necessary support or information. The contact details are readily available, and the company is committed to maintaining open channels of communication.
About PCI Biotech
PCI Biotech Holding ASA is an innovative biopharmaceutical company specializing in light-mediated therapies. The company's unique approach focuses on delivering drugs to targeted tissues effectively, significantly enhancing treatment outcomes. As a forward-thinking entity on the Oslo stock exchange, PCI Biotech has been exploring the vast potential of its technology across various applications.
Importance of Transparency
In line with its values, PCI Biotech places a strong emphasis on transparency and proactive communications with its investors. This commitment is reflected in its regular updates and disclosures, ensuring that all stakeholders are informed and engaged with the company’s progress.
Frequently Asked Questions
When will the PCI Biotech H1 2025 results be shared?
The results will be presented during a live webcast on a Friday morning from 08:30 AM to 09:00 AM CET.
How can I attend the presentation?
Interested participants can join the presentation via the official PCI Biotech website, where the session will be streamed live.
Will there be a chance to ask questions during the session?
Yes, there will be an interactive Q&A session following the presentation, with opportunities to submit questions in advance or live during the event.
Can I access the interim report online?
Absolutely! The interim report will be available on the company's website and news web portal from 07:00 AM CET on the day of the presentation.
Who can I contact for more information?
For more information, you can reach out to Ronny Skuggedal, the CEO/CFO, via email or phone, as provided in the announcement.
